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Abstract
To achieve the great potential of siRNA based gene therapy, safe and efficient systemic delivery in 
vivo is essential. Here we report reductively responsive hydrogel nanoparticles with highly 
uniform size and shape for systemic siRNA delivery in vivo. “Blank” hydrogel nanoparticles with 
high aspect ratio were prepared using continuous particle fabrication based on PRINT (particle 
replication in nonwetting templates). Subsequently, siRNA was conjugated to “blank” 
nanoparticles via a disulfide linker with a high loading ratio of up to 18 wt %, followed by surface 
modification to enhance transfection. This fabrication process could be easily scaled up to prepare 
large quantity of hydrogel nanoparticles. By controlling hydrogel composition, surface 
modification, and siRNA loading ratio, siRNA conjugated nanoparticles were highly tunable to 
achieve high transfection efficiency in vitro. FVII-siRNA conjugated nanoparticles were further 
stabilized with surface coating for in vivo siRNA delivery to liver hepatocytes, and successful gene 
silencing was demonstrated at both mRNA and protein levels.
Abstract
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1. INTRODUCTION
RNA interference (RNAi) with small interfering RNA (siRNA) is a promising 
biotechnology, which has great potential to treat cancer and other diseases.1–3 As a 
negatively charged biological molecule, naked siRNA is unable to penetrate the cell 
membrane effectively.4 In addition, siRNA is unstable and susceptible to degradation by 
RNase in serum. A safe and efficient delivery method is necessary to protect siRNA and 
facilitate its delivery to the cytoplasm. A suitable delivery carrier should assist in 
overcoming multiple biological barriers for systemic delivery in vivo, to enable prolonged 
circulation time, target-specific cellular uptake, and enhanced endosomal escape.5 
Nanoparticles are of extreme interest for siRNA delivery as a result of the ease to control 
particle composition and surface properties. Different types of nanoparticles have been 
developed to deliver siRNA, which include lipid nanoparticles,6–17 polymer-based 
nanoparticles,18–23 peptide-based nanoparticles,24,25 calcium phosphate nanoparticles,26,27 
and other inorganic nanoparticles.28,29 Nevertheless, it remains a challenge to achieve 
systemic delivery in vivo. To date, there are only a few examples of systemic siRNA delivery 
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in vivo with lipids,6–8 cationic polymers,3,30 and lipid-coated calcium phosphate.26,31 The 
majority of these examples are based on physical entrapment of siRNA, which may lead to 
premature release during blood circulation.
Particle replication in nonwetting templates (PRINT) is a particle fabrication technology 
capable of producing nano-particles or microparticles with highly uniform shape, size, and 
composition.32–36 We previously reported the use of PRINT based hydrogel nanoparticles to 
deliver siRNA in vitro.37 In that work, siRNA was loaded when nanoparticles were being 
fabricated, requiring water to be used as solvent (see further explanations in Supporting 
Information, Part 2), which does not favor continuous particle fabrication process. 
Therefore, batch fabrication method was used. To enable the full potential of PRINT 
technology by using continuous particle fabrication38 to efficiently produce large quantity of 
highly uniform particles, we developed a new “post-fabrication” siRNA loading method. 
With this new method, reductively responsive nanoparticles were efficiently prepared with 
continuous fabrication process. The loading efficiency of siRNA was also greatly improved. 
The resulting luciferase-siRNA conjugated nanoparticles were able to efficiently knock 
down luciferase expression in vitro. Furthermore, the surface of nanoparticles were modified 
to facilitate systemic delivery of siRNA in vivo, and efficient gene silencing of FVII in liver 
hepatocytes was achieved with FVII-siRNA conjugated nanoparticles.
2. MATERIALS
Tetraethylene glycol monoacrylate (HP4A) was synthesized in house39 and kindly provided 
by Dr. Ashish Pandya and Mathew Finnis. DMAPMA (N -[3-(dimethylamino)propyl]-
methacrylamide) was from TCI America. 2-(Methacryloyloxy)-ethyltrimethylammonium 
chloride solution, poly(acrylic acid) (Mw = 1800), S-acetylthioglycolic acid N-
hydroxysuccinimide ester, and TPO (diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide) 
were from Sigma-Aldrich. mPEG5k acrylate and mPEG5k-NH2 were from 
CreativePEGWorks. NHS-PEG3.4k-COOH was from Laysan Bio. Poly-L-lysine 
hydrobromide and DL-dithiothreitol were from Sigma. EDC (1-ethyl-3-(3-
(dimethylamino)propyl)carbodiimide hydrochloride), hydrox-ylamine hydrochloride and 
SPDP were from Thermo Scientific. AEM (2-aminoethyl methacrylate hydrochloride) and 
PEG700 diacrylate were from Acros Organics. Sulfo-NHS (N-hydrox-ysulfosuccinimide 
sodium salt) was from Chem-Impex International. Sense strand amine modified siRNA was 
synthesized by Novartis. The sequences of siRNA: Luciferase sense amine-modified 5′-
NH2-C6-GAUUAUGUCCGGUUAUGUAUU-3′. antisense 5′-
UACAUAACCGGACAUAAUCUU-3′; FVII sense 5′-NH2-C6-
uGucuuGGuuucAAuuAAAuu; antisense 5′-UUuAAUUGAAACcAAGAcAuu-3′. 
Luciferase siRNA was used as control for in vivo experiments in mice, and FVII siRNA was 
used as control for in vitro assays on HeLa/luc cells.
3. EXPERIMENTAL METHODS
3.1. “Blank” Nanoparticle Fabrication
The method for nanoparticle fabrication on a PRINT based continuous particle fabrication 
instrument was described in detail previously.40 The preparticle solution was prepared by 
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dissolving 5 wt % of the various reactive monomers in methanol. A representative 
preparticle solution composition was shown in Table S1. Nanoparticles were transferred to 
plasdone harvest sheets and harvested with sterile water with a yield of 0.8 mg/foot. SEM 
micrograph of “blank” nanoparticles was shown in Figure S1. DyLight 680 labeled 
nanoparticles were prepared similarly with the addition of DyLight 680 succimide.
3.2. siRNA Loading and Nanoparticle Surface Modification
First, “Blank” nanoparticles were suspended in anhydrous DMF at 2 mg/mL. NHS-PEG3.4k-
COOH (1 equiv to nanoparticle mass) and pyridine (2 equiv to nanoparticle mass) were 
added. The reaction proceeded at r.t. for 12 h, followed by centrifugation (14 000 rpm, 20 
min, 4 °C) to collect nanoparticles. Next, nanoparticles were resuspended in PBS at 2 
mg/mL and SPDP (0.2 equiv to nanoparticle mass in CH3CN) was added. The suspension 
was vortexed gently at r.t. for 6 h. Nanoparticles were collected by centrifugation (14 000 
rpm, 20 min, 4 °C) and subsequently washed twice with sterile water. Subsequently, siRNA-
SH (synthetic procedure was described in Supporting Information) was added to a 
suspension of nanoparticles (10 mg/mL) in PBS, which was shaken at r.t. for 12 h. 
Nanoparticles conjugated with siRNA were collected by centrifugation (14 000 rpm, 20 min, 
4 °C), which were washed twice with 10× PBS and twice with sterile water. Finally, 
nanoparticles were suspended in PBS (1 mg/mL). EDC (3 equiv), sulfo-NHS (10 equiv), and 
PLL (10 equiv) were added. Reaction proceeded at r.t. for 12 h. Nanoparticles were 
centrifuged and washed once with 10× PBS and twice with sterile water. The resulting 
hydrogel nanoparticles were used for cellular study in vitro. To conduct hemolysis assay and 
deliver siRNA in vivo, nanoparticles (4 mg/mL) were incubated in a solution of mPEG5k-
PAA (synthetic procedure was described in Supporting Information, 10 equiv in PBS) for 30 
min. Resulting nanoparticles were collected with centrifugation (14 000 rpm, 20 min, 4 °C) 
and washed once with PBS.
3.3. Nanoparticle Characterization
Scanning electron microscopy (SEM) enabled imaging of hydrogels that were dispersed on a 
silicon wafer and coated with 2.2 nm of Au/Pd (Hitachi S-4700). ξ-potential and dynamic 
light scattering measurements (approximate measurements of hydrogel dynamic size of rod-
like particles based on a mathematical model of spherical particles) were conducted on 20 
μg/mL particle dispersions in 1 mM KCl or 0.1× PBS buffer using a Zetasizer Nano ZS 
particle analyzer (Malvern Instruments Inc.).
3.4. Analysis of siRNA by Gel Electrophoresis
2.5% agarose gel in TBE buffer was prepared with 0.5 μg/mL of ethidium bromide. To study 
release of siRNA from hydrogel nanoparticles, nanoparticles were incubated in 1× PBS, 
with 5 mM reduced glutathione (GSH). Aliquots of particle dispersions were centrifuged (14 
000 rpm, 15 min, 4 °C) for recovery of the supernatant at various time points which were 
then stored at −20 °C until analysis on gel. For evaluation of protection of siRNA by 
nanoparticles, siRNA hydrogels were incubated in 1× PBS supplemented with 30% FBS at 
37 °C for given times, followed by incubation in 10× PBS (5 mM glutathione) for 4 h at 1.2 
mg/mL and 37 °C to release all siRNA. Twelve microliters of sample (supernatants from 
particle dispersions, siRNA solutions, or particle dispersions) was mixed with 3 μL of 6× 
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loading buffer (60% glycerol, 0.12 M EDTA in DEPC-treated water) and loaded into the gel. 
After applying 70 V/cm for 25 min, the gel was imaged with ImageQuant LAS 4000 (GE). 
Analysis of siRNA band intensity was conducted with ImageJ software for quantification. 
siRNA loading ratio was calculated by comparing the maximum amount of siRNA released 
from nanoparticles to the nanoparticle mass. Conversion efficiency of siRNA conjugation 
was calculated by comparing the maximum amount of siRNA released from nanoparticles to 
the amount of siRNA used to conjugate nanoparticles.
3.5. Cells Culture and in vitro Assays
Luciferase-expressing HeLa cell line (HeLa/luc) was from Xenogen. HeLa/luc cells were 
maintained in DMEM high glucose supplemented with 10% FBS, 2 mM L-glutamine, 100 
units/mL penicillin and 100 μg/mL streptomycin, 1 mM sodium pyruvate, and nonessential 
amino acids. All media and supplements were from GIBCO except for FBS which was from 
Mediatech, Inc.
HeLa/luc cells were plated in 96-well plates at 5000/well and incubated overnight at 37 °C. 
Cells were dosed with fluorescently tagged particles in OPTI-MEM (Invitrogen) at 37 °C for 
4 h for cell uptake studies. Fluorescently tagged particles were prepared by incorporation of 
fluorescein O-acrylate in the particle composition and copolymerization of these monomers 
into particle matrix. After incubation, cells were trypsinized and treated with 0.1% trypan 
blue to quench the fluorescein fluorescence from particles associated with the cell surface. 
Cells were then washed and fixed in 1% paraformaldehyde/DPBS and analyzed by CyAn 
ADP flow cytometer (Dako). The cell uptake was represented as the percentage of cells that 
were positive in fluorescein fluorescence.
For in vitro cytotoxicity and luciferase expression assays, cells were dosed with particles or 
lipofectamine 2000 (Invitrogen)/siRNA (2:1, wt/wt) in OPTI-MEM at 37 °C for 4 h, then 
particles were removed, and complete grow medium was added for another 48 h incubation 
at 37 °C. Cell viability was evaluated with Promega CellTiter 96 AQueous One Solution 
Cell Proliferation Assay, and luciferase expression level was evaluated with Promega Bright-
Glo Luciferase Assay according to manufacturer’s instructions. Light absorption or bio-
luminescence was measured by a SpectraMax M5 plate reader (Molecular Devices). The 
viability or luciferase expression of the cells exposed to PRINT particles was expressed as a 
percentage of that of cells grown in the absence of particles. Half-maximal effective 
concentration (EC50) of siRNA required to elicit gene knockdown was determined by 
applying the dose-dependent luciferase expression data to a log(inhibitor) vs response 
variable slope nonlinear function in GraphPad Prism software.
3.6. Hemolysis Assay
Blood from C57BL/6 mice were washed twice with HBSS buffer. 1.5 × 108 red blood cells 
were placed in each well of round-bottom 96-well plate and treated with particle 
formulations of various concentrations for 30 min at 37 °C. Cells were then centrifuged at 
1500 rpm for 10 min, and supernatants were transferred into another plate and absorbance 
was measured at 540 nm. 0.5% Triton X-100 and 5 mg/mL PEG8000 were used as positive 
and negative controls, respectively.
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3.7. Biodistribution of NP in Mice
C57BL/6 mice were intravenously injected with 0.5 mg particles labeled with DyLight 680. 
Twenty-four h post injections, mice were euthanized, and the major organs (liver, spleen, 
lung, kidney, and heart) were harvested. The resected organs were imaged by IVIS Lumina 
fluorescence imaging system (PerkinElmer) with excitation at 675 nm and emission 
measured at 720 nm. The percentage of NP fluorescence in each organ against the total 
fluorescence recovered from all the major organs was calculated and presented.
3.8. in vivo FVII Silencing in Mice
All procedures used in animal studies were approved by the Institutional Animal Care and 
Use. C57BL/6 mice were from Jackson Laboratories and used at 6–10 weeks old. Particle 
formulations were administered intravenously via tail vein injection, at 4 or 6 mg siRNA/kg. 
48 h post treatment, liver tissues were harvested for analyses.
For qRT-PCR assay of mRNA level, liver tissues were harvested from euthanized mice and 
preserved in RNALater. qRT-PCR was done as previously published.41 Primers used were: 
(Mus Factor VII) forward: ACA AGT CTT ACG TCT GCT TCT; reverse: CAC AGA TCA 
GCT GCT CAT TCT; probe: FTC TCA CAG TTC CGA CCC TCA AAG TCQ; (Mus β-
Actin) forward: CTG CCT GAC GGC CAG GTC; reverse: CAA GAA GGA AGG CTG 
GAA AAG A; probe: FCA CTA TTG GCA ACG AGC GGT TCC GQ; F: 5′-fluorescein 
(FAM); Q: quencher (TAMRA).
FVII protein level in mouse plasma was assayed with BIOPHEN VII assay kit (Aniara 
Corporation) according to manufacturer’s instructions. A standard curve was constructed 
using samples from PBS-injected mice and relative Factor VII expression was determined by 
comparing treated groups to untreated PBS control.
For immunohistochemistry analysis, particles were labeled with DyLight 680 dye. Particle 
formulations were administered intravenously via tail vein injection, at 4 mg siRNA/kg. 
Twenty-four h post treatment, liver tissues were harvested and snap frozen in O.C.T medium 
and cryosected into 5 μm sections. Sections were fixed in ice cold acetone for 5 min, briefly 
air-dried, and rehydrated in 1× PBS for 15 min. The tissue sections were then blocked with 
1% bovine serum albumin in PBS for 20 min, and sequentially stained with antimouse 
MARCO (Invitrogen) and goat antirat IgG-Alexa Fluor 488 in 1% BSA/PBS. Tissue 
sections were also stained with phalloidin-Alexa Fluor 555 (Invitrogen) and DAPI (Sigma). 
Images were collected with Zeiss710 confocal laser scanning microscope (Carl Zeiss).
3.9. Statistical Analysis
Liver FVII mRNA and plasma FVII protein measurements were analyzed by One-Way 
ANOVA followed by Bonferroni’s Multiple Comparison test.
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4. RESULTS AND DISCUSSION
4.1. Nanoparticle Preparation and Characterization
We chose to make a rod-shaped particle with high aspect ratio: 80 × 80 × 320 nm (L × W × 
H, 80 × 320 nm hereafter) for enhanced cell uptake42 and improved in vivo PK 
previously40,43 compared to 200 × 200 cylindrical particles we previously used for siRNA 
delivery.37 Compared to the direct siRNA incorporation method previously reported,37 the 
current formulation strategy made particles and loaded siRNA in two separate steps. We first 
prepared 80 × 320 nm hydrogel nanoparticles using the PRINT based continuous particle 
fabrication instrument with a high efficiency.40 A representative “blank” nanoparticle 
composition (Table S1) includes: (1) AEM (2-aminoethyl methacrylate) as a reaction handle 
for siRNA conjugation; (2) cationic tertiary amine DMAPMA (N-[3-
(dimethylamino)propyl]methacrylamide) to improve transfection efficiency; (3) mPEG5k-
acrylate as a nanoparticle stabilizer. This composition also includes cross-linker (PEG700 
diacrylate), photo initiator (TPO), and hydrophile (tetra-ethylene glycol monoacrylate). This 
composition dissolved in volatile methanol is fully compatible with mold based continuous 
fabrication process without using aqueous content for siRNA dissolution. 300 mg of 
nanoparticles with highly uniform size, shape, and composition were prepared within 30 
min. As illustrated in Scheme 1, the resulting “blank” nanoparticles were treated with SPDP 
(succinimidyl 3-(2-pyridyldithio)propionate),44 which reacted with primary amine groups on 
nanoparticles. Subsequently, by incubating these nanoparticles in thiol modified siRNA 
(siRNA modification method described in the Supporting Information),45 siRNA was 
conjugated to nanoparticles via a disulfide linker to enable reduction-sensitive release of 
cargo. To further enhance transfection efficiency, nanoparticles were treated with 
polyammonium polymers (poly-L-lysine) along with an activation agent of EDC (1-Ethyl-3-
(3-(dimethylamino)-propyl)carbodiimide) and sulfo-NHS (N-hydroxysulfosuccinimide 
sodium salt). The SEM micrograph (Figure 1a and S1) indicated that the size, shape, and 
integrity of these rod-shape nanoparticles were well-retained after siRNA loading and 
surface modification. Dynamic light scattering measurement in water using a mathematical 
model of spherical particles indicated that the 80 × 320 nm rod-shape nanoparticles had an 
overall hydrodynamic size of 368.2 ± 4.2 nm with a narrow size distribution (PDI = 0.06).
4.2. Reductively Responsive Release of siRNA
Electrostatic complexation of siRNA with cationic nanoparticles may have the issue of 
premature release during circulation in blood. In order to avoid this issue, siRNA was 
conjugated to hydrogel nanoparticles via a “pro-drug” strategy. The disulfide linker in these 
“pro-siRNA” hydrogel nanoparticles is stable in the physiological environment, but 
cleavable in the intracellular reducing environment. As shown in Figure 1b, these reductively 
responsive hydrogel nanoparticles are expected to maintain encapsulation of siRNA while 
circulating in blood and release the cargo after entering cells. The release profile of siRNA 
loaded nanoparticles is shown in Figure 1c. While no siRNA was released in PBS, siRNA 
was quickly released when incubated in 5 mM glutathione,46 which mimics the intracellular 
reducing condition.37
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4.3. Protection of siRNA from Degradation
Another important requirement for siRNA carriers is the capability to protect cargo from 
degradation by RNase. To determine if hydrogel nanoparticles provided conjugated siRNA 
protection from nuclease degradation, a stability assay was carried out. As shown in Figure 
1d, siRNA conjugated to hydrogel nanoparticles was stable after incubation in 30% FBS for 
24 h. By comparison, naked siRNA was completely degraded by 30% FBS in the same 
period of incubation.
4.4. siRNA Delivery Evaluation in vitro
Before these siRNA conjugated nanoparticles were used for systemic delivery in vivo, 
nanoparticle composition was adjusted to evaluate gene silencing efficiency in vitro. PEG-
based PRINT hydrogel particles without targeting ligand generally enter nonphagocytic cells 
via endocytosis.42 Positive charges of cationic nanoparticles enhance nonspecific 
interactions with cells, improve endocytosis, and assist endosomal escape likely via so-
called “proton sponge” effect.37,47,48 We were able to tune the positive charge density of 
these nanoparticles by varying their composition and surface modification of PLLs. 
Luciferase gene silencing was evaluated by treating HeLa/luc cells with luciferase–siRNA 
conjugated nanoparticles of different surface modifications, chemical compositions, and 
siRNA loading ratios.
First, three PLLs of different molecular weights (1–5k, 15–30k, and 30–70k) were used to 
modify nanoparticle surface properties, when the content of the tertiary amine macromer 
DMAPMA was fixed at 40 wt % and siRNA was constantly charged at 40 wt %. Luciferase 
expressing HeLa/luc cells were treated with luciferase-siRNA conjugated nanoparticles in a 
media with reduced serum (OPTI-MEM) for 4 h. Nanoparticles were subsequently removed, 
and cells were incubated at 37 °C for another 48 h. Dose-dependent knock-down of 
luciferase expression was observed with a maximum gene silencing of 90%, when 
nanoparticles were surface modified with PLL 15–30k (Figure 2a). Nanoparticles modified 
with PLL 15–30k showed no cytotoxicity (Figure 2b). By 30k. Four different ratios of 
siRNA (weight percentage to “blank” nanoparticles), 100, 40, 20, and 10 wt %, were 
charged and conjugated to “blank” nanoparticles. The siRNA loading ratios of the resulting 
nanoparticles were 18.2, 10.0, 5.8, and 2.6 wt %, respectively (Table 1). The loading 
efficiencies of siRNA comparison, nanoparticles modified with PLL 1–5k showed low 
transfection efficiency, and nanoparticles modified with the large molecular weight PLL 
(30–70k) led to high cytotoxicity.
Next, the content of the tertiary amine macromer DMAPMA was varied with the siRNA 
charging ratio fixed at 40 wt % and surface modification with PLL 15–30k. The dimethyl 
amine group in DMAPMA may assist cellular uptake and increases pH buffering capacity to 
enhance endosomal escape due to the “proton sponge” effect. Luciferase transfected HeLa 
cells were dosed with hydrogel nanoparticles fabricated with different DMAPMA contents 
of 10, 20, and 40 wt % (weight percent to macromers in preparticle solution). As illustrated 
in Figure 2c (cell uptake and viability assays are shown in Figure S4 and S5), nanoparticles 
with the highest DMAPMA content of 40 wt % had the highest transfection efficiency, while 
those with 10 and 20 wt % DMAPMA were less efficient in delivering luciferase-siRNA 
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into HeLa/luc cells. Therefore, we chose 40 wt % DMAPMA as the best nanoparticle 
composition to enhance transfection.
Furthermore, nanoparticles were conjugated with different ratios of siRNA to evaluate the 
influence of siRNA loading ratio on transfection efficiency. “Blank” nanoparticles were 
fabricated with 40 wt % DMAPMA and surface modified with PLL 15–30k. Four different 
ratios of siRNA (weight percentage to “blank” nanoparticles), 100, 40, 20, and 10 wt %, 
were charged and conjugated to “blank” nanoparticles. The siRNA loading ratios of the 
resulting nanoparticles were 18.2, 10.0, 5.8, and 2.6 wt %, respectively (Table 1). The 
loading efficiencies of siRNA were between 18% and 29%. Silencing of luciferase 
expression with hydrogel nanoparticles of different siRNA loading ratios was evaluated 
(Figure 2d). EC50 was calculated to be 509, 150, 116, and 80 nM, respectively. 
Nanoparticles with the lowest siRNA loading ratio had the lowest EC50 and were the most 
efficient at gene silencing based on the amount of siRNA dosed. It is possible that, with a 
large quantity of siRNA conjugated (up to 18 wt %), the relatively lower content of cationic 
polymers would lower the transfection efficiency, including less efficient cellular uptake and 
reduced endosomal escape capability. The highest transfection efficiency achieved by our 
hydrogel nanoparticles (EC50 = 80 nM) is comparable to that achieved by lipofectamine 
2000 (EC50 = 28 nM, Figure S6), a commercially available transfection agent, which is 
widely used for in vitro transfection. We chose nanoparticles loaded with 10.0 wt % siRNA, 
which combined a high loading ratio and efficient gene silencing, for further in vivo animal 
studies.
4.5. siRNA Delivery in vivo
The above studies indicate that hydrogel nanoparticles with surface modification of PLL 15–
30k, chemical composition of 40 wt % DMAPMA, and siRNA loading ratio of 10 wt % 
achieved efficient transfection in vitro in a media with reduced serum (OPTI-MEM). 
Nanoparticles of this composition were positively charged (ζ-potential = +31.8 mV). 
Positive nanoparticles may suffer from reduced transfection efficiency in serum-containing 
medium as a result of serum protein coating. The coating with negatively charged serum 
protein would change the nanoparticle surface property and significantly lower the capability 
of cellular uptake and endosomal escape. Notably, the luciferase expression assay of our 
luciferase–siRNA conjugated nanoparticles showed no reduction in transfection efficiency in 
10% FBS compared to those in medium with reduced serum (Figure S7). This result 
demonstrated that nanoparticles were stabilized, most likely by mPEG5k acrylate used to 
fabricate “blank” nanoparticles and/or NHS-PEG3.4k-COOH used to modify the nanoparticle 
surface.
The above formulation was used for systemic delivery in vivo. Cationic nanoparticles could 
be subject to quick clearance during circulation in blood due to opsonization.49 Our previous 
study demonstrated that PEGylation of hydrogel NP significantly improved circulation of 
NP.40 Therefore, mPEG modified poly(acrylic acid) (mPEG5k-PAA) was used to coat siRNA 
loaded cationic nanoparticles to further stabilize them for in vivo applications. The resulting 
nanoparticles had a slightly negative ζ -potential of −5.8 mV and a size of 331.5 ± 4.4 nm 
(PDI = 0.06) in 0.1× PBS (pH = 7.4). Distribution study of the cationic NP and mPEG5k-
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PAA coated NP in mice showed that both accumulated most efficiently in liver (>40%), 
followed by accumulation in spleen and kidney at similar levels (Figure S8). About 20% of 
cationic NP was also found in lung, likely due to opsonization of positively charged NP in 
blood and formation of larger aggregates, which is often filtered by lung. On the other hand, 
only 5% of mPEG5k-PAA coating was in lung, and there was about 10% more of this NP in 
liver instead. Further examination of liver sections (Figure S9) indicated that mPEG5k-PAA 
coating helps to stabilize NP in vivo and get internalized by hepatocytes and other liver cells, 
while cationic NP tended to aggregate and was less taken up by cells.
The toxicity of these mPEG5k-PAA coated nanoparticles to red blood cells was studied with 
a hemolysis assay (Figure 3a). Red blood cells (RBCs) were treated with hydrogel 
nanoparticles at 0.111, 0.333, and 1 mg/mL and incubated at 37 °C for 0.5 h. Minimal RBC 
lysis was observed with up to 1 mg/mL of either FVII-siRNA or luciferase-siRNA 
conjugated nanoparticles. This result indicates these nanoparticles have minimal toxicity to 
red blood cells when administered for systemic delivery.
Studies have been reported on using siRNA to treat liver-related diseases.49,50 Since 
biodistribution study as well as liver examination indicated efficient accumulation of our 
hydrogel particles in liver parenchymal cells, we chose to show the gene silencing potential 
of this system in liver in the initial investigation. Coagulation factor VII (FVII) that is 
produced by liver hepatocytes has been reported in multiple siRNA delivery systems.8,51–53 
In addition, measurements of FVII at mRNA and blood protein levels have been well 
studied. Therefore, mouse hepatic FVII was chosen as the gene target to test the efficacy of 
siRNA delivery and gene silencing. Mice were dosed with FVII-siRNA loaded nanoparticles 
via intravenous administration at 6 mg/kg or 4 mg/kg (weight ratio of siRNA to mice). 
Nanoparticles loaded with luciferase-siRNA were administered at the same dose as the 
control. Liver tissues and blood were collected 48 h post treatments for mRNA and FVII 
protein analyses, respectively. Figure 3b showed that 6 mg/kg FVII-siRNA resulted in ~75% 
reduction of the FVII mRNA level, while the lower dose of 4 mg/kg FVII-siRNA gave a 
moderate reduction of approximately 40%. The reduction of the FVII protein level in plasma 
followed the same trend, with 6 mg/kg FVII-siRNA administration leading to a 40% 
decrease in FVII protein level in blood (Figure S10). Since protein is more stringently 
regulated, the decrease in protein level is smaller compared to that of mRNA level. 
Optimization of treatment regime may be needed for desired knockdown levels.
A closer examination of liver tissues from mice treated with hydrogel nanoparticles (labeled 
with DyLight 680 and loaded with FVII-siRNA) via intravenous administration was done by 
confocal microscopy. Figure 3c showed a representative image of liver sections from mice 
treated with nanoparticles (separate channels shown in Figure S11). It could be seen that 
large quantities of particles (green) were accumulated in almost all cells, including Kupffer 
cells (magenta) and other cells (red) which should be mostly hepatocytes, the mesenchymal 
cells of liver (70–85% of total liver cells). In addition, images taken along z-axis showed that 
particles were distributed at different depth of tissues (Figure S12), further demonstrating 
that the particles were able to penetrate liver tissues and reach intracellular environment. 
These results together demonstrated the capability of the nanoparticles to deliver cargo to 
liver hepatocytes and silence gene expression.
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siRNA conjugated polymeric nanoparticles with a uniform shape, size, and composition 
have been developed and used for systemic delivery in vivo. Building on our previous work, 
the new “post-fabrication” siRNA loading method allows us to use PRINT based continuous 
particle fabrication to prepare large quantity of nanoparticles with a high efficiency. The 
cargo was conjugated to nanoparticles with a loading ratio of up to 18 wt % and a loading 
efficiency of up to 29%. The composition, surface modification, and siRNA conjugation 
ratio of nanoparticles are highly tunable to achieve efficient luciferase gene silencing in vitro 
with minimum cytotoxicity. Furthermore, FVII-siRNA loaded nanoparticles are capable of 
efficient knock-down of FVII expression via systemic delivery in vivo. We are currently 
further optimizing this hydrogel formulation for other targets, including tumors, and also 
developing particles constituted with biodegradable materials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) SEM micrograph of 80 × 320 nm hydrogel nanoparticles conjugated with siRNA (scale 
bar 4 μm); (b) illustration of reductively responsive hydrogel behavior under physiological 
and intracellular conditions; (c) time-dependent incubation of pro-siRNA hydrogels (1 
mg/mL) in PBS and under reducing conditions (glutathione, 5 mM) at 37 °C; (d) Integrity of 
siRNA soluble or conjugated to hydrogels after exposure to 30% fetal bovine serum (FBS) 
in PBS over time; after FBS treatment, siRNA was extracted from nanoparticles using 5 mM 
glutathione in 10× PBS and analyzed with gel electrophoresis.
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(a) Luciferase expression and (b) viability of Hela/luc cells treated with cationic hydrogel 
nanoparticles surface modified with PLL of different molecular weights. Luciferase 
expression in HeLa/luc cells treated with nanoparticles of (c) different tertiary amine 
DMAPMA contents and (d) different siRNA loading ratios. Cells were dosed with 
nanoparticles in a media with reduced serum (OPTI-MEM) for 4 h followed by the removal 
of nanoparticles and 48 h incubation in media. The error bars represent standard deviation 
from triplicate wells in the same experiment. The amount of siRNA loaded was calculated 
based on that was released in gel electrophoresis assays. Nonspecific siRNA was used as a 
control.
Ma et al. Page 16














(a) Hemolysis assay with mPEG-PAA coated and FVII-siRNA or control-siRNA conjugated 
nanoparticles at 0.111, 0.333, and 1 mg/mL; 0.5% Triton X-100 was used as the positive 
control, and 5 mg/mL PEG8000 as the negative control. in vivo FVII knock-down (48 h after 
intravenous administration) with different doses of FVII-siRNA or control-siRNA 
conjugated nanoparticles: (b) FVII mRNA level in liver with qRT-PCR assay. (c) Confocal 
micrograph of liver tissue (24 h after intravenous administration of nanoparticles) from mice 
treated with DyLight 680 labeled nanoparticles (green). Cellular actin cytoskeleton was 
stained with phalloidin (red), macrophages with MARCO (magenta), and nuclei with DAPI 
(blue). Scale bar represents 20 μm. Antiluciferase siRNA conjugated nanoparticles were 
used as the control. Results are combinations of two independent experiments with n = 4–5 
for each experiment; data are shown as mean ± SEM *p < 0.05; **p < 0.01; ***p < 0.001.
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Schematic Illustration of “Post-Fabrication” siRNA Loading and Surface Modification: (a) 
NHS-PEG3.4k-COOH, DMF, Pyridine; (b) SPDP, PBS/CH3CN; (c) siRNA-SH, PBS; (d) 
Poly-L-lysine, EDC, Sulfo-NHS, PBS
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100 wt % 18.2 wt % 18% 509
40 wt % 10.0 wt % 25% 150
20 wt % 5.8 wt % 29% 116
10 wt % 2.6 wt % 26% 80
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